Search for Trials

Why did we establish ClinLife?

ClinLife was launched with the aim to improve the premises for the conduction of clinical trials in the USA, Canada and Europe and to speed up the development of new medications. We were especially motivated by following factors:

• Delays: around 80% of all clinical research trials conducted worldwide have to begin with delay, due to a lack of patients participating in the studies. This also delays the accessibility of new qualified drugs to the public.
• No listing: up until the year 2006 not one comprehensive, up-to-date register for clinical research trials existed. Since then ClinLife has become the largest clinical trial community in  Europe, expanding to the U.S. and Canada, aiming at promoting research in medicine and healthcare.
• Low participation:A national study conducted in 2007 revieled that even though 57% of American adults are aware of clinical trials and furthermore regard a participation as a likely health benefit, only 7% have actually participated in a clinical trial.
• Neglected publication: The large gap between awareness and participation indicate an insufficient publication of clinical trials.
• Poor public perception:Only 25% believe that trial patients receive honest and accurate information and are not treated like "guinea pigs."
• High demand: the amount of required patients for a clinical trial is on a rising branch. Nowadays the required number of patients in order to get a new drug approved has risen a 50% over the last 20 years.

Due to globalization and the wide acceptance of the Internet it only seemed natural to use a publicly accessible portal in the World Wide Web (www.) to inform and increase participation in clinical research. The foundation of ClinLife was born.

Our priority is a cost-free access to trials on ClinLife for both patients and healthy volunteers. Thus, the financing of ClinLife and the information update must be ensured by the conductors of clinical trials. That way all parties benefit.

• Interested patients may find clinical trials that offer new treatment methods for their ailment and have the possibility to acquire according information anonymously and without any obligations.
• Sponsor and Clinical research centres gain direct access to new potential trial participants and can recruit the necessary amount of participants ─ and stay within their given time frame.

Conclusion: Both parties profit from timely approval or rejection of new drugs or medical devices:

• Patients receive an accelerated access to effective new therapies and treatments
• Sponsors can minimize their cost by saving time finding potential participants